IRIS
BUTINI, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.447
EU - Europa 10.806
AS - Asia 3.148
SA - Sud America 516
AF - Africa 84
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 11
Totale 26.036
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.351
GB - Regno Unito 3.043
IT - Italia 2.023
IE - Irlanda 1.557
CN - Cina 1.322
SG - Singapore 872
SE - Svezia 816
RU - Federazione Russa 739
DE - Germania 731
UA - Ucraina 731
BR - Brasile 463
FR - Francia 448
HK - Hong Kong 379
FI - Finlandia 305
IN - India 144
TR - Turchia 136
ES - Italia 74
KR - Corea 74
CA - Canada 69
AT - Austria 53
CZ - Repubblica Ceca 52
CI - Costa d'Avorio 42
BE - Belgio 39
NL - Olanda 34
VN - Vietnam 30
RO - Romania 26
GR - Grecia 24
IR - Iran 24
AU - Australia 19
BD - Bangladesh 19
PL - Polonia 19
AR - Argentina 15
JP - Giappone 14
PT - Portogallo 14
EG - Egitto 13
MX - Messico 13
ZA - Sudafrica 12
CH - Svizzera 11
IL - Israele 11
IQ - Iraq 11
MA - Marocco 11
UZ - Uzbekistan 11
AZ - Azerbaigian 10
EU - Europa 10
SA - Arabia Saudita 10
EE - Estonia 9
LT - Lituania 9
DK - Danimarca 8
LV - Lettonia 8
PE - Perù 8
PK - Pakistan 8
AE - Emirati Arabi Uniti 7
CL - Cile 7
CO - Colombia 7
ID - Indonesia 7
KG - Kirghizistan 7
KZ - Kazakistan 6
PA - Panama 6
VE - Venezuela 6
BG - Bulgaria 5
BO - Bolivia 5
GE - Georgia 5
HU - Ungheria 5
JO - Giordania 5
LA - Repubblica Popolare Democratica del Laos 5
NZ - Nuova Zelanda 5
RS - Serbia 5
EC - Ecuador 4
JM - Giamaica 4
MY - Malesia 4
BY - Bielorussia 3
KW - Kuwait 3
LK - Sri Lanka 3
NO - Norvegia 3
TH - Thailandia 3
TW - Taiwan 3
AL - Albania 2
AM - Armenia 2
HR - Croazia 2
LB - Libano 2
MD - Moldavia 2
OM - Oman 2
PH - Filippine 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
DZ - Algeria 1
HN - Honduras 1
IM - Isola di Man 1
IS - Islanda 1
KH - Cambogia 1
LU - Lussemburgo 1
MC - Monaco 1
NG - Nigeria 1
NI - Nicaragua 1
NP - Nepal 1
QA - Qatar 1
Totale 26.029
Salva come PNG Salva come JPEG
Città #
Southend 2.794
Fairfield 1.754
Dublin 1.542
Ashburn 1.080
Woodbridge 788
Chandler 787
Siena 729
Seattle 655
Wilmington 642
Santa Clara 613
Cambridge 603
Jacksonville 602
Houston 601
Ann Arbor 443
Singapore 424
Beijing 409
Hong Kong 378
Princeton 264
Nanjing 209
Dearborn 146
Florence 134
Helsinki 127
Milan 126
New York 125
Fremont 115
Izmir 114
Boardman 106
Shanghai 101
Bengaluru 91
San Diego 87
San Mateo 84
Rome 81
Washington 79
Nanchang 74
Seoul 67
Moscow 66
Düsseldorf 60
Los Angeles 57
Munich 57
Málaga 56
Lancaster 49
Lappeenranta 48
Hebei 46
Abidjan 42
Brno 42
Shenyang 40
London 39
Jiaxing 38
Redwood City 35
São Paulo 35
Vienna 35
Aachen 34
Brussels 34
Jinan 33
Kunming 33
The Dalles 32
Tianjin 32
Norwalk 31
Venezia 30
Guangzhou 28
Nuremberg 28
Portsmouth 28
San Francisco 28
Changsha 27
Menlo Park 26
Ottawa 26
Frankfurt am Main 25
Ningbo 25
Dong Ket 23
Lauterbourg 23
Toronto 23
Council Bluffs 22
Turku 22
Belo Horizonte 18
Parma 18
Brescia 17
Trieste 17
Turin 17
Hangzhou 16
Hefei 16
Naples 15
Pisa 15
Prato 15
Avellino 14
Timisoara 14
Brooklyn 13
Zhengzhou 13
Dallas 12
Dhaka 12
Marietta 12
Rio de Janeiro 12
Columbus 11
Salerno 11
San Giovanni Valdarno 11
Tashkent 11
Palermo 10
Tokyo 10
Baku 9
Boston 9
Changchun 9
Totale 18.689
Salva come PNG Salva come JPEG
Nome #
Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages 314
Development of novel cyclic peptides as pro-apoptotic agents 289
Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents 288
Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]- N -[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues 286
(S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: further exploration of bioisosteric replacements and structural and biological investigation 282
Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain 271
iPSC-derived neurons profiling reveals GABAergic circuit disruption and acetylated α-tubulin defect which improves after iHDAC6 treatment in Rett syndrome 269
Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies 251
Synthetic spirocyclic endoperoxides: new antimalarial scaffolds 244
Natural Compounds and Synthetic Drugs to Target FAAH Enzyme 242
A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin 240
Bridged bicyclic 2,3-dioxabicyclo[3.3.1]nonanes as antiplasmodial agents: Synthesis, structure-activity relationships and studies on their biomimetic reaction with Fe(II) 240
Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems 235
The 1-(2,3-dichlorophenyl)-piperazine-to-aripiprazole ratio at steady state in rats and schizophrenic patients 234
Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain 232
First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents 231
Synthesis, Molecular Modelling and Biological Studies of 3-hydroxy-pyrane-4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors 227
Old but gold: tracking the new guise of Histone Deacetylase 6 (HDAC6) enzyme as a biomarker and therapeutic target in rare diseases 225
Targeting Dopamine D3and Serotonin 5-HT1Aand 5-HT2AReceptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies 224
A Jocic-type approach for a practical and scalable synthesis of pyrrolonaphthoxazepine (PNOX)-based potent proapoptotic agents 222
Activation of the Wnt pathway by small peptides: rational design, synthesis and biological evaluation 221
Identification of novel fluorescent probes preventing PrP(Sc) replication in prion diseases 219
Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking 212
1H-Cyclopentapyrimidine-2,4(1H,3H)-dione-Related Ionotropic Glutamate Receptors Ligands. Structure-Activity Relationships and Identification of Potent and Selective iGluR5 Modulators 208
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine d3 and serotonin 5-HT 1A and 5-HT2A receptors: Design, synthesis, and effects on behavior 207
A stereoselective route to 6-substituted pyrrolo-1,5-benzoxazepinones and their analogues 206
Structural characterization of Giardia duodenalis thioredoxin reductase (gTrxR) and computational analysis of its interaction with NBDHEX 202
Targeting clinically-relevant metallo-β-lactamases: from high-throughput docking to broad-spectrum inhibitors 198
Selective Kainate Receptor (GluK1) Ligands Structurally Based upon 1H-Cyclopentapyrimidin-2,4(1H,3H)-dione: Synthesis, Molecular Modeling, and Pharmacological and Biostructural Characterization 198
Telomerase-based cancer therapeutics: a review on their clinical trials 197
Optimization of 4-Aminoquinoline/Clotrimazole-Based Hybrid Antimalarials: Further Structure-Activity Relationships, in vivo Studies, and Preliminary Toxicity Profiling 196
null 195
Novel quinolone-based potent and selective HDAC6 inhibitors: synthesis, molecular modeling studies and biological investigation 194
Non-Nucleoside Inhibitors of Human Adenosine Kinase: Synthesis, Molecular Modeling, and Biological Studies 192
Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability 189
Synthetic studies toward 1,2-dioxanes as precursors of potential endoperoxide-containing antimalarials 188
Microwave-assisted synthesis of 4-quinolylhydrazines followed by nickel boride reduction: a convenient approach to 4-aminoquinolines and derivatives 188
Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease 188
Mimicking the Intramolecular Hydrogen Bond: Synthesis, Biological Evaluation, and Molecular Modeling of Benzoxazines and Quinazolines as Potential Antimalarial Agents 188
A light in the dark: State of the art and perspectives in optogenetics and optopharmacology for restoring vision 188
Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases 188
Discovery of Potent Inhibitors of Human and Mouse Fatty Acid Amide Hydrolases 188
Pyrrolo 1,3 benzothiazepine-based Atypical Antipsychotic Agents. Synthesis, Structure-Activity Relationship, Molecular Modeling, and Biological Studies 187
Discovery of Bishomo(hetero)arylpiperazines as Novel Multifunctional Ligands Targeting Dopamine D-3 and Serotonin 5-HT1A and 5-HT2A Receptors 186
Exploiting Protein Fluctuations at the Active-Site Gorge of Human Cholinesterases: Further Optimization of the Design Strategy to Develop Extremely Potent Inhibitors 185
The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity 185
Synthesis and Antiplasmodial Activity of Bicyclic Dioxanes as Simplified Dihydroplakortin Analogues 184
A synthetic strategy to bridged 2,3,8-trioxabicyclo[3,3,1]nonane endoperoxides 184
Synthesis and structure–activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds 183
Synthesis of Dihydroplakortin, 6-epi-Dihydroplakortin, and Their C10-Desethyl Analogues 182
Design and Synthesis of Potent Antimalarial Agents Based on Clotrimazole Scaffold: Exploring an Innovative Pharmacophore 182
A stereoselective approach to peptidomimetic BACE1 inhibitors 182
Design, synthesis, and structure-activity relationship studies of 4-quinolinyl- and 9-acrydinylhydrazones as potent antimalarial agents 180
Unravelling the response of chronic lymphocytic leukemia to a novel class of anticancer agents, the pyrrolonaphthoxazepines (PNOXs) 180
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 179
The Interactions of the 5-HT3 Receptor with Quipazine-Like Arylpiperazine Ligands. The Journey Track at the End of the First Decade of the Third Millennium 177
Quinolylhydrazones as novel inhibitors of Plasmodium falciparum serine protease PfSUB1 176
Pyrroloquinoxaline Derivatives as High-Affinity and Selective 5-HT3 Receptor Agonists: Synthesis, Further Structure-Activity Relationships, and Biological Studies 175
Selective Fatty Acid Amide Hydrolase Inhibitors as Potential Novel Antiepileptic Agents 174
Development of Antitubercular Compounds Based on a 4-Quinolylhydrazone Scaffold. Further Structure-activity Relationship Studies 173
Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation 173
Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains 172
Novel peptidomimetics as BACE-1 inhibitors: synthesis, molecular modeling, and biological studies 172
Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant P. falciparum strains. Synthesis and molecular modeling 172
Synthetic studies toward bicyclic endoperoxides presenting polar side chains 171
Development of a multiplexed activity-based protein profiling assay to evaluate activity of endocannabinoid hydrolase inhibitors 171
Malaria chemotherapy: recent advances in drug development 169
Retinitis pigmentosa and retinal degenerations: deciphering pathways and targets for drug discovery and development 169
Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders 168
ARYL PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROPSYCHIATRY DISORDERS. 167
Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors 167
Endocannabinoid Modulation of Predator Stress-Induced Long-Term Anxiety in Rats 166
A palladium-catalyzed synthetic approach to new Huperzine A analogues modified at the pyridone ring 165
Computational tool for fast in silico evaluation of hERG K+ channel affinity 162
Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors 161
Novel aryl piperazine derivatives with medical utility 160
Pyrroloquinoxaline hydrazones as fluorescent probes for amyloid fibrils 160
Discovery of Huperzine A/Tacrine Hybrids as Potent Inhibitors of Human Cholinesterases Targeting Their Mid-gorge Recognition Sites 160
Specific Targeting of Hepatitis C Virus NS3 RNA Helicase. Discovery of the Potent and Selective Competitive Nucleotide-Mimicking Inhibitor QU663 159
Specific Targeting of Peripheral Serotonin 5-HT3 Receptors. Synthesis, Biological Investigation and Structure Activity Relationships 158
Multifunctional Cholinesterase and Amyloid Beta Fibrillization Modulators. Synthesis and Biological Investigation 157
Pyrrolo[1,5]benzoxa(thia)zepines as a New Class of Potent Apoptotic Agents. Biological Studies and Identification of an Intracellular Location of Their Drug Target 156
A Straightforward Approach for Engineering Efficacy and Selectivity at GPCRs 154
COMPOUNDS WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY 153
Identification of a novel arylpiperazine scaffold for fatty acid amide hydrolase inhibition with improved drug disposition properties 152
Site-directed mutagenesis of key residues unveiled a novel allosteric site on human adenosine kinase for Pyrrolobenzoxa(thia)zepinone non-nucleoside inhibitors 152
Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations 151
Screening and phenotypical characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) inhibitors as multistage antischistosomal agents 148
Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation 148
Neuronal high affinity sodium-dependent glutamate transporters (EAATs): targets for the development of novel therapeutics against neurodegenerative diseases 147
An efficient approach to chiral C8/C9-Piperazino-Substituted 1,4-Benzodiazepin-2-ones as peptidomimetic scaffolds 146
Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants 146
Disease modifying anti-Alzheimer’s drugs: inhibitors of human cholinesterases interfering with β-amyloid aggregation 144
'Polycondensed heterocycles. Part 12: an approach to the synthesis of 2-acetyl-1'-methyl-1,2,3,4-tetrahydrospiro[isoquinoline-1,4'-pyrrolidine]-2'-one 142
Rational design of the first difluorostatone-based PfSUB1 inhibitors 142
Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells 142
Identification of novel 3-Hydroxy-pyran-4-one derivatives as potent HIV-1 integrase inhibitors using in silico structure-based combinatorial library design approach 142
Extra virgin olive oil extracts of indigenous Southern Tuscany cultivar act as anti-inflammatory and vasorelaxant nutraceuticals 141
Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition 140
Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the ‘‘primer grip’’ region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants 140
Totale 18.915
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.999
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.999
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020268 0 0 0 0 0 0 0 0 0 0 0 268
2020/20214.033 161 338 204 358 263 609 331 463 322 475 317 192
2021/20222.602 229 307 226 156 123 73 133 111 123 330 294 497
2022/20233.081 178 302 415 392 337 602 89 242 277 100 93 54
2023/20242.984 107 55 276 137 183 797 895 42 30 99 124 239
2024/20255.106 165 223 658 303 620 297 173 282 616 250 490 1.029
Totale 26.582